No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
01952 EVEREST MED-B
- 24.150
- +0.650+2.77%
Trading Apr 25 14:53 CST
7.83BMarket Cap-8402P/E (TTM)
24.800High22.700Low3.20MVolume23.550Open23.500Pre Close76.36MTurnover0.99%Turnover RatioLossP/E (Static)324.18MShares32.20052wk High1.43P/B7.83BFloat Cap10.32052wk Low--Dividend TTM324.18MShs Float104.800Historical High--Dividend LFY8.94%Amplitude5.980Historical Low23.839Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Everest Medicines' Loss Widens in 2023
Everest Medicines' (HKG:1952) net loss attributable to equity holders widened to 844.5 million yuan in the year ended Dec. 31, 2023, from a loss of 247.3 million yuan a year ago, according to a Wednes
雲頂新耀-B：2023年度報告
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 8%, and many positive results of Nifukang appeared in WCN2024
Genting Xinyao B (01952) rose more than 8%. As of press release, it had risen 8.12% to HK$23.3, with a turnover of HK$67.237 million.
[Broker Focus] Western Securities maintains Genting Xinyao (01952) holdings” rating indicates that several catalysts will soon be implemented this year
According to the Western Securities Research Report, Genting Xinyao (01952) made many advances in drug registration and commercialization in 2023. Driven by new product sales, the company's revenue increased dramatically in 2023. Eiga and Nifukang achieved sales of 99 million yuan and 21 million yuan respectively. If non-cash projects are not included, the company's gross margin exceeds 80%, and the company's innovative layout is gradually entering the harvest period.
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 6% in the intraday period and surged more than 20% this week, and the IgA nephropathy market reappeared with 10 billion acquisitions
Genting Xinyao B (01952) rose more than 6% in the intraday period, with a cumulative increase of more than 20% this week. As of press release, it rose 4.1% to HK$26.65, with a turnover of HK$87.213,400.
Cansino Biotech (06185), the leading healthcare market, surged 15.12%, and Beijing, Guangzhou, and Zhuhai issued pharmaceutical innovation support policies
Jinwu Financial News | The healthcare sector led the market. Hang Seng Healthcare Index rose 1.93%. Among the constituent stocks, Cansino Biotech (06185) rose 15.12%, Junshi Biotech (01877) rose 11.9%, Genting Xinyao (01952) rose 7.8%, Yiming Angke (01541) rose 7.79%, Pharmaceuticals (02268) rose 5.98%, and Tiger Pharmaceuticals (03347) rose 5.8%. According to the news, the Beijing Municipal Medical Security Administration issued “On “Certain Measures to Support the High-Quality Development of Innovative Pharmaceuticals by 9 Departments Including the Beijing Municipal Medical Security Administration” (202
Comments
CEO of Everest Medicines, Rogers Yongqing Luo, is confident that the appointments of Ms. Zeng and Mr. Liang will expedite the company's strategic growth. They are anticipated to spearhead their teams and foster strategic integration, promoting successful commercialization of Everest's products and long-term value creation.
Press Release: Everest Medicines Strengthens Management Team With Appointments of Chief Medical Officer and Chief Product Officer 1
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
$Hang Seng Index(800000.HK$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
1
$EVEREST MED-B(01952.HK$ will potebtially reap benefits from new Covid vaccine approval by FDA
2
$EVEREST MED-B(01952.HK$ On September 13, Genting Sunshine announced that it would introduce Providence's mRNA COVID-19 vaccine at a total price of 2.583 billion yuan, and the two parties will also cooperate in the development of two mRNA vaccines in the future.
1
1
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg